Laura Poling

Laura Poling" alt="Laura Poling" itemprop="image">

Company: C4 Therapeutics

Job title: Director of Biology


CFT8634, a Potent & Selective Degrader of BRD9 for the Treatment of SMARCB1-perturbed Cancers 11:30 am

CFT8634 is an orally bioavailable heterobifunctional degrader that induces ubiquitination and degradation of BRD9 by the proteasome. CFT8634 promotes potent and selective BRD9 degradation and dosedependent tumor growth inhibition in cell- and patient-derived preclinical SMARCB1-perturbed xenograft models. Degradation of BRD9 by CFT8634 offers a promising and novel approach to address this class of difficult-to-treat diseases.Read more

day: Day Two

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.